# Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

> **NCT01137955** · NA · COMPLETED · sponsor: **Columbia University** · enrollment: 50 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01137955
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137955, "Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01137955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*